142 related articles for article (PubMed ID: 15224193)
21. Prognostic role of myeloid cell leukemia-1 protein (Mcl-1) expression in human gastric cancer.
Likui W; Qun L; Wanqing Z; Haifeng S; Fangqiu L; Xiaojun L
J Surg Oncol; 2009 Oct; 100(5):396-400. PubMed ID: 19582795
[TBL] [Abstract][Full Text] [Related]
22. Expression of the antiapoptosis gene Survivin predicts poor prognosis of stage III gastric adenocarcinoma.
Song KY; Jung CK; Park WS; Park CH
Jpn J Clin Oncol; 2009 May; 39(5):290-6. PubMed ID: 19336448
[TBL] [Abstract][Full Text] [Related]
23. Molecular markers in gastric cancer: can p53 and bcl-2 protein expressions be used as prognostic factors?
Zafirellis K; Karameris A; Milingos N; Androulakis G
Anticancer Res; 2005; 25(5):3629-36. PubMed ID: 16101192
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the prognostic value of a panel of tissue tumor markers and established clinicopathological factors in patients with gastric cancer.
Wiksten JP; Lundin J; Nordling S; Kokkola A; Haglund C
Anticancer Res; 2008; 28(4C):2279-87. PubMed ID: 18751407
[TBL] [Abstract][Full Text] [Related]
25. Fhit expression in gastric adenocarcinoma: correlation with disease stage and survival.
Capuzzi D; Santoro E; Hauck WW; Kovatich AJ; Rosato FE; Baffa R; Huebner K; McCue PA
Cancer; 2000 Jan; 88(1):24-34. PubMed ID: 10618602
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of Bcl-2 and p53 expression in gastric cancer.
Lee HK; Lee HS; Yang HK; Kim WH; Lee KU; Choe KJ; Kim JP
Int J Colorectal Dis; 2003 Nov; 18(6):518-25. PubMed ID: 12811476
[TBL] [Abstract][Full Text] [Related]
27. Relationship between HER-2, COX-2, p53 and clinicopathologic features in gastric adenocarcinoma. Do these biomarkers have any prognostic significance?
Ugraş N; Özgün G; Ocakoğlu G; Yerci Ö; Öztürk E
Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():176-81. PubMed ID: 25910300
[TBL] [Abstract][Full Text] [Related]
28. Prediction of sites of recurrence in gastric carcinoma using immunohistochemical parameters.
Saito H; Osaki T; Murakami D; Sakamoto T; Kanaji S; Ohro S; Tatebe S; Tsujitani S; Ikeguchi M
J Surg Oncol; 2007 Feb; 95(2):123-8. PubMed ID: 17262742
[TBL] [Abstract][Full Text] [Related]
29. Relationship between E-cadherin gene mutation and p53 gene mutation, p53 accumulation, Bcl-2 expression and Ki-67 staining in diffuse-type gastric carcinoma.
Fricke E; Keller G; Becker I; Rosivatz E; Schott C; Plaschke S; Rudelius M; Hermannstädter C; Busch R; Höfler H; Becker KF; Luber B
Int J Cancer; 2003 Mar; 104(1):60-5. PubMed ID: 12532420
[TBL] [Abstract][Full Text] [Related]
30. Relationship between the long-term effects of intraperitoneal chemotherapy and the expression of p53 and p21 in patients with gastric carcinoma at stage IIIa and stage IIIb.
Ikeguchi M; Saito H; Katano K; Gomyo Y; Tsujitani S; Maeta M; Kaibara N
Int Surg; 1997; 82(2):170-4. PubMed ID: 9331847
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of p53 protein expression for patients with gastric cancer--a multivariate analysis.
Maehara Y; Tomoda M; Hasuda S; Kabashima A; Tokunaga E; Kakeji Y; Sugimachi K
Br J Cancer; 1999 Mar; 79(7-8):1255-61. PubMed ID: 10098768
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of the heat shock protein HSP70 family and p53 protein and prognosis for patients with gastric cancer.
Maehara Y; Oki E; Abe T; Tokunaga E; Shibahara K; Kakeji Y; Sugimachi K
Oncology; 2000 Feb; 58(2):144-51. PubMed ID: 10705241
[TBL] [Abstract][Full Text] [Related]
33. High expression of L-type amino-acid transporter 1 (LAT1) in gastric carcinomas: comparison with non-cancerous lesions.
Ichinoe M; Mikami T; Yoshida T; Igawa I; Tsuruta T; Nakada N; Anzai N; Suzuki Y; Endou H; Okayasu I
Pathol Int; 2011 May; 61(5):281-9. PubMed ID: 21501294
[TBL] [Abstract][Full Text] [Related]
34. P53-protein accumulation and MDM2-protein overexpression in gastric carcinomas. No apparent correlation with survival.
Kasper HU; Schneider-Stock R; Mellin W; Günther T; Roessner A
Pathol Res Pract; 1999; 195(12):815-20. PubMed ID: 10631716
[TBL] [Abstract][Full Text] [Related]
35. Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival.
Casneuf VF; Fonteyne P; Van Damme N; Demetter P; Pauwels P; de Hemptinne B; De Vos M; Van de Wiele C; Peeters M
Cancer Invest; 2008 Oct; 26(8):852-9. PubMed ID: 18853313
[TBL] [Abstract][Full Text] [Related]
36. Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma.
Gomyo Y; Ikeda M; Osaki M; Tatebe S; Tsujitani S; Ikeguchi M; Kaibara N; Ito H
Cancer; 1997 Jun; 79(11):2067-72. PubMed ID: 9179052
[TBL] [Abstract][Full Text] [Related]
37. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer.
Borner MM; Brousset P; Pfanner-Meyer B; Bacchi M; Vonlanthen S; Hotz MA; Altermatt HJ; Schlaifer D; Reed JC; Betticher DC
Br J Cancer; 1999 Feb; 79(5-6):952-8. PubMed ID: 10070896
[TBL] [Abstract][Full Text] [Related]
38. Impact of the expression of cyclin-dependent kinase inhibitor p27Kip1 and apoptosis in tumor cells on the overall survival of patients with non-early stage gastric carcinoma.
Ohtani M; Isozaki H; Fujii K; Nomura E; Niki M; Mabuchi H; Nishiguchi K; Toyoda M; Ishibashi T; Tanigawa N
Cancer; 1999 Apr; 85(8):1711-8. PubMed ID: 10223564
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological and immunohistochemical markers after radical gastrectomy for gastric cancer.
Potrc S; Gadiijev E; Hajdinjak T; Kavalar R
Hepatogastroenterology; 2007; 54(73):308-14. PubMed ID: 17419281
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of p53 predicts shorter survival in diffuse type gastric cancer.
Lee WJ; Shun CT; Hong RL; Wu MS; Chang KJ; Chen KM
Br J Surg; 1998 Aug; 85(8):1138-42. PubMed ID: 9718015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
